title: Polymeric sustained local drug delivery system for the prevention of vascular intimal hyperplasia.
abstract: Anastomotic intimal hyperplasia (IH) is a major cause of both autologous vein and synthetic vascular graft failure. We have previously published data suggesting that cyclosporin may reduce the development of IH in a canine model. However, systemic administration of cyclosporin could create serious adverse effects. Therefore, it is our long-term goal to test the hypothesis that the controlled local release of cyclosporin from a polymeric vascular wrap will prevent the development of IH. To test this hypothesis, we developed a controlled release vascular wrap (sheet/ring) using a poly(ethylene glycol) (PEG) hydrogel. Sterilization of the polymers was performed using the ethylene oxide and hydrogen peroxide sterilization methods. It was found that except for one combination (8000 molecular weight and 1:1 crosslinking ratio), the differences in the swelling ratios for the sterilized and unsterilized hydrogels were not statistically significant. Release studies from unsterilized and ethylene oxide-sterilized PEG hydrogels were conducted. It was found that release lasted for approximately 50 h for sterilized as well as unsterilized PEG hydrogels. Acute animal studies, to test the deployment of both the polymeric sheets and rings to the adventitial surface of native arteries and veins, were completed successfully.
authors.affiliation: Department of Chemical Engineering, University of Akron, Akron, Ohio 44325, USA.
authors.forename: Deenu
authors.initials: D
authors.lastname: Kanjickal
authors.forename: Stephanie
authors.initials: S
authors.lastname: Lopina
authors.forename: M Michelle
authors.initials: MM
authors.lastname: Evancho-Chapman
authors.forename: Steven
authors.initials: S
authors.lastname: Schmidt
authors.forename: Duane
authors.initials: D
authors.lastname: Donovan
authors.forename: Sara
authors.initials: S
authors.lastname: Springhetti
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage; D004285:Dogs; D016503:Drug Delivery Systems; D004343:Drug Implants / Q000494:pharmacology / Q000592:standards*; D005268:Femoral Vein; D020100:Hydrogels / Q000627:therapeutic use; D006965:Hyperplasia / Q000188:drug therapy / Q000517:prevention & control*; D007601:Jugular Veins; D007700:Kinetics; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D013242:Sterilization; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D004343:Drug Implants; D020100:Hydrogels; D011092:Polyethylene Glycols; D016572:Cyclosporine